Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:7 Issue:10 Number:6 ISSN#:2563-5476
RCT
ACE Report #10354
Ace Report Cover Cannabis

Tetrahydrocannabinol similar in efficacy & safety as placebo in improving spasticity and pain in MS


How to Cite

OrthoEvidence. Tetrahydrocannabinol similar in efficacy & safety as placebo in improving spasticity and pain in MS. ACE Report. 2018;7(10):6. Available from: https://myorthoevidene.com/AceReport/Report/10354

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis

Clin Ther. 2018 Sep;40(9):1467-1482. doi: 10.1016/j.clinthera.2017.01.016

Contributing Authors: G van Amerongen K Kanhai AC Baakman J Heuberger E Klaassen TL Beumer RLM Strijers J Killestein J van Gerven A Cohen GJ Groeneveld

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

24 patients diagnosed with progressive multiple sclerosis (MS) experiencing pain and moderate spasticity were randomly assigned to either treatment with an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) or placebo for 4 weeks. Improvements in symptoms were assessed by objective and subjective measures, and the incidence and nature of adverse events were monitored. The results demonstrated n...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE